Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Accumulated Expenses (2022 - 2025)

Gossamer Bio's Accumulated Expenses history spans 4 years, with the latest figure at $15.8 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 4.22% year-over-year to $15.8 million; the TTM value through Dec 2025 reached $15.8 million, up 4.22%, while the annual FY2025 figure was $15.8 million, 4.22% up from the prior year.
  • Accumulated Expenses reached $15.8 million in Q4 2025 per GOSS's latest filing, down from $19.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $26.7 million in Q4 2023 to a low of $8.9 million in Q1 2024.
  • Average Accumulated Expenses over 4 years is $15.5 million, with a median of $15.4 million recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: tumbled 43.08% in 2024, then surged 87.69% in 2025.
  • A 4-year view of Accumulated Expenses shows it stood at $20.5 million in 2022, then rose by 29.94% to $26.7 million in 2023, then crashed by 43.08% to $15.2 million in 2024, then grew by 4.22% to $15.8 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's Accumulated Expenses are $15.8 million (Q4 2025), $19.3 million (Q3 2025), and $15.6 million (Q2 2025).